| Bioactivity | Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer[1]. |
| Invitro | Ontuxizumab (0-100 μg/mL；12 小时) 诱导 CD248 内化并剂量依赖性地降低了 46% 的人周皮细胞表面的 CD248[1]。 |
| In Vivo | Ontuxizumab (50 mg/kg；静脉注射，每天 5 次，连续 5 天) 在人 CD248 敲入小鼠显示抗肿瘤作用[1]。 Animal Model: |
| Name | Ontuxizumab |
| CAS | 946415-62-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015 Sep 22;6(28):25429-40. |